HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts...Read more
Prestigious Hadassah Medical Center Joins Yale, Johns Hopkins, Tel Aviv Sourasky and IMCA, in Evaluating the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate Vancouver, Canada, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND),...Read more
BP1.15205 is a differentiated chemical scaffold, demonstrating high potency and selectivity in preclinical studies with a favorable safety profile and the potential for once-daily dosing Topline clinical data expected in 2026 PLYMOUTH MEETING, Pa. / Nov 19, 2025 / Business Wire...Read more
FDA Response Streamlines Path to Commercial Production of PF614 SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system...Read more
Following Priority Review, the U.S. FDA granted HYRNUO® (sevabertinib) approval for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by...Read more
EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...Read more
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Nutex Health | 38.81 34.59 | $151.00 |
| Regeneron Pharmaceuticals | 34.50 4.91 | $737.26 |
| Mettler-Toledo | 16.75 1.19 | $1,421.18 |
| Exact Sciences | 15.28 17.73 | $101.46 |
| argenx | 12.19 1.33 | $926.78 |
| IDEXX Laboratories | 10.54 1.51 | $707.64 |
| PACS Group | 9.78 58.11 | $26.61 |
| Guardant Health | 9.48 9.52 | $109.03 |
| Natera | 8.95 4.10 | $227.30 |
| Medpace | 8.50 1.44 | $600.68 |
| Madrigal Pharmaceuticals | 8.40 1.51 | $564.00 |
| Intuitive | 7.82 1.38 | $572.46 |
| Vertex Pharmaceuticals | 7.36 1.75 | $428.39 |
| Movano Health | 7.13 229.26 | $10.24 |
| GRAIL | 7.03 7.99 | $95.00 |
| iRhythm Technologies | 6.70 4.00 | $174.00 |
| Abivax | 5.83 5.16 | $118.78 |
| Waters | 5.55 1.48 | $381.80 |
| Company | Volume | Last Trade |
|---|---|---|
| Mobile-health Network Solutions | 41,334,299 | $2.60 |
| Exact Sciences | 31,178,830 | $101.46 |
| Plus Therapeutics | 17,307,545 | $0.51 |
| Applied Therapeutics | 8,688,155 | $0.29 |
| Pfizer | 8,108,632 | $24.69 |
| Psyence Biomedical | 7,569,202 | $2.12 |
| InMed Pharmaceuticals | 6,186,487 | $1.36 |
| PACS Group | 5,597,839 | $26.61 |
| Recursion | 4,750,028 | $4.23 |
| Clearmind Medicine | 4,486,240 | $0.21 |
| Nuvation Bio | 4,450,445 | $7.22 |
| Nano-X Imaging | 2,969,444 | $3.73 |
| Can-Fite BioPharma | 2,740,723 | $0.35 |
| Sangamo Therapeutics | 2,642,977 | $0.42 |
| Moderna | 2,612,471 | $23.98 |
| Novo Nordisk | 2,553,322 | $49.17 |
| Annexon | 2,498,998 | $4.81 |
| Abbott | 2,447,077 | $123.82 |
| Olema Oncology | 2,334,002 | $23.79 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
